

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A pharmaceutical preparation which comprises 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmacologically acceptable salt thereof in combination with N-[2-cyano-4-(2,2-dimethyl-propylamino)-pyrimidin-5-ylmethyl]-4-(4-methyl-piperazin-1-yl)-benzamide or a pharmacologically acceptable salt thereof for simultaneous, sequential or separate use.

Claim 2 (previously presented): The pharmaceutical preparation according to claim 1; wherein its use is for the treatment of malignant diseases, bone metastasis, cancer cell growth, or/and cancer therapy-induced bone loss.

Claim 3 (currently amended): A method of treating a patient suffering from ~~a malignant disease, bone metastasis, cancer cell growth, or/and cancer therapy-induced bone loss~~ comprising administering to the patient an effective amount of the pharmaceutical preparation according to claim 1.

Claim 4 (canceled)

Claim 5 (previously presented): A pharmaceutical composition comprising zoledronic acid and a cathepsin K inhibitor for the inhibition of bone metastasis, cancer cell growth or/and inhibition of cancer-therapy-induced bone loss.

Claims 6-7 (canceled)